building extraordinary life science companies on both sides of the atlantic

AdoRxLogoWeb

AdoRx Therapeutics

Edinburgh, United Kingdom

AdoRx is developing new modulators of the adenosine pathway for the treatment of cancer.

VIEW WEBSITE >>

APellisMaybe

Apellis Pharmaceuticals

Louisville, Kentucky

Apellis is a NASDAQ listed company developing therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within haematology, ophthalmology, and nephrology. 

VIEW WEBSITE >>

Caldan Therapeutics

Edinburgh, United Kingdom

Caldan, a spin-out company from the Universities of Glasgow and Southern Denmark, is developing novel therapeutics targeting free fatty acid receptors for metabolic diseases. The lead programme aims to develop a selective FFA4 (GPR120) agonist for Non-Alcoholic Steatohepatitis (NASH). 

VIEW WEBSITE >>

Clyde Biosciences

Glasgow, United Kingdom

Clyde Biosciences, a spin-out company from the University of Glasgow, has developed a pioneering technology (CellOPTIQ) to rapidly evaluate cardiotoxicity risk in pharmaceuticals.  

VIEW WEBSITE >>

Confluence logo

Confluence Life Sciences

St. Louis, Missouri

Confluence Life Sciences, Inc., a technology-based company focusing on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases, was acquired by Aclaris Therapeutics (ACRS). 

Acquired August 2017

Curve Therapeutics

London, United Kingdom

Curve a spin-out from the University of Southampton, Curve is deploying its MicrocycleTM platform to build a pipeline of first-in-class therapeutics targeting protein-protein interactions.  Curve’s goal is to transform the discovery of new therapeutics through functional screening against intractable targets in their native cellular environment.

VIEW WEBSITE >>

DUNAD Therapeutics

Cambridge, United Kingdom

Dunad is focusing on the development of next-generation small molecule therapeutics based on its highly differentiated, tuneable and targeted protein degradation technology.

VIEW WEBSITE >>

EMISmall 3

Edinburgh Molecular Imaging

Edinburgh, United Kingdom

EM Imaging, a spin-out company from the University of Edinburgh, is a clinical phase biotechnology company with a highly novel C-Met molecular targeting technology platform.  It is developing a radiotherapeutic agent for treatment in cancer, alongside its fluorescent optical imaging agent.   

VIEW WEBSITE >>

enterprise-therap

Enterprise Therapeutics

Brighton, United Kingdom

Enterprise Therapeutics is a clinical stage company dedicated to the research and development of novel therapies for the treatment of respiratory diseases through the modulation of ion channels.  

VIEW WEBSITE >>

Eternygen

Berlin, Germany

Eternygen is focused on the discovery of inhibitors of NaCT, a novel target which, “as the longevity gene”, is also known as INDY (I am Not Dead Yet), for the treatment of dietary-related metabolic diseases. 

VIEW WEBSITE >>

Epsilogen

London, United Kingdom

Epsilogen (formerly IGEM Therapeutics) is a clinical stage company, spun-out from King’s College London, is developing IgE-based antibody therapeutics for the treatment of cancer. 

VIEW WEBSITE >>

Harpoon Medical, Inc.

Harpoon Medical, Inc.

Baltimore, Maryland

Harpoon Medical, Inc. a medical device, spun-out from the University of Maryland, Baltimore (UMB) commercializing a minimally invasive, image-guided surgical tool for beating heart mitral valve repair, as acquired by Edwards Lifesciences Corporation (EW). 

Acquired December 2017

Leucid Bio

London, United Kingdom

Leucid Bio, a spin out company from King’s College London is focused on the development of new treatments for cancer. The company is developing a pioneering technology utilising engineered T cells.

VIEW WEBSITE >>

Libra Therapeutics

San Diego, California

Libra Therapeutics is a US biotech focused on developing novel therapeutics for neurodegenerative diseases by normalizing intracellular trafficking and autophagy in neuronal cells.

VIEW WEBSITE >>

Lunac Therapeutics

Leeds, United Kingdom

LUNAC Therapeutics, a spin-out company from the University of Leeds, is developing next generation oral anticoagulants for the treatment and prevention of life-threatening thrombotic events.

VIEW WEBSITE >>

Macomics

Edinburgh, United Kingdom

Macomics, an early-stage immuno-oncology company, spun-out from the University of Edinburgh, its developing next-generation therapies to modulate macrophages, increasing the body’s immune defence against tumours.

VIEW WEBSITE >>

Mironid

Glasgow, United Kingdom

Mironid is developing proprietary drug candidates that modulate the activity of key phosphodiesterase 4 (PDE4) enzymes in chronic inflammatory and degenerative kidney diseases.

VIEW WEBSITE >>

NodTheraLogo

NodThera

Cambridge, United Kingdom

NodThera is a clinical stage company developing NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation.

VIEW WEBSITE >>

RapidPulse, Inc.

Miami, Florida

RapidPulse, a spin out from medical device incubator and engineering firm Syntheon, is developing a novel RapidPulse aspiration system to treat ischemic stroke.

VIEW WEBSITE >>

Slate Bio, Inc.

Charlottesville, Virginia

Slate Bio, a spin out from the University of Virginia, is developing next generation IL-2 therapies that restore the body’s natural immunological response in various diseases.

VIEW WEBSITE >>

SIRAKOSS logo

SIRAKOSS

Aberdeen, United Kingdom

SIRAKOSS, a spin-out company from the University of Aberdeen, is developing nano-synthetic bone graft substitutes to facilitate bone repair utilising advanced nanostructures to catalyse faster bone regeneration.

Acquired November 2020

Theolytics

Oxford, United Kingdom

Theolytics, is a UK biotech focused on creating a step-change in the oncolytic viral therapy field, by using its patient-centric phenotypic screening platform.

VIEW WEBSITE >>

Topas Therapeutics

Hamburg, Germany

Topas is a clinical stage therapeutics company using ground-breaking nanoparticle technology to target autoimmune and inflammatory diseases via the induction of antigen-specific immune tolerance in the liver.

VIEW WEBSITE >>